Travere Therapeutics

About Travere Therapeutics

Travere Therapeutics is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for people living with rare diseases, with a particular focus on rare kidney and metabolic disorders.

Products & Services

Sparsentan for FSGS:A treatment under development for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disorder.

Pegtibatinase:A therapy in the pipeline for rare metabolic conditions.

FILSPARI:A non-immunosuppressive treatment for IgA Nephropathy (IgAN) that has received full FDA approval.

Therapies for Rare Diseases:Focused on therapeutic areas including IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS), Classical Homocystinuria (HCU), and Cystinuria.

FILSPARI (sparsentan)

Specialties

Rare Kidney Diseases Metabolic Disorders IgA Nephropathy (IgAN) Focal Segmental Glomerulosclerosis (FSGS) Classical Homocystinuria (HCU) Cystinuria Rare diseases Nephrology IgA nephropathy (IgAN) Focal segmental glomerulosclerosis (FSGS) Classical homocystinuria (HCU)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 475000000 MR: - FA: $475.0 million FAN: 475000000	D: 2026-05-06 FD: 2026-05-06	4 investors
2	RT: Convertible Senior Notes T: - FT: Convertible Senior Notes	A: 400000000 MR: - FA: $400 million FAN: 400000000	D: 2026-05-05 FD: 2026-05-05	3 investors
3	RT: Public Offering T: - FT: Public Offering	A: 143800000 MR: - FA: approximately $143.8 million FAN: 143800000	D: 2024-11-12 FD: 2024-11-12	3 investors
4	RT: Public Offering T: - FT: Public Offering	A: 125000000 MR: - FA: $125.0 million FAN: 125000000	D: 2024-11-07 FD: 2024-11-07	3 investors
5	RT: Public Offering T: - FT: Public Offering	A: 230000000 MR: - FA: approximately $230.0 million FAN: 230000000	D: 2023-03-03 FD: 2023-03-03	4 investors
6	RT: Public Offering T: - FT: Public Offering	A: 175000000 MR: - FA: 175,000,000 FAN: 175000000	D: 2023-02-27 FD: 2023-02-27	4 investors

Debt Latest

2026-05-06

$475.0M

4 investors (Pro only)

Convertible Senior Notes 2026-05-05

$400.0M

Public Offering 2024-11-12

$143.8M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

E

Eric Dube

President & Chief Executive Officer

C

Chris Cline

Chief Financial Officer

A

Angela Giannantonio

Chief People Officer

P

Peter Heerma

Chief Commercial Officer

J

Jula Inrig

Chief Medical Officer

C

Casey Logan

Chief Business Officer

View 15 more team members with Pro

Unlock Full Team Directory

Recent News